|
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. |
60.00% |
|
Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. |
60.00% |
|
Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marr |
60.00% |
|
Vitamin D and prostate cancer risk: a review of the epidemiological literature. |
60.00% |
|
New biochemical mechanisms of the anticancer effect of Ukrain in the treatment of cancer of the urinary bladder |
60.00% |
|
Anti-angiogenic therapies for metastatic colorectal cancer. |
60.00% |
|
Ukrain treatment in carcinoma of the cervix (case report) |
60.00% |
|
Nuts and green tea key to cancer treatment? |
60.00% |
|
Clinical studies of Ukrain in healthy volunteers (phase 1). |
60.00% |
|
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. |
60.00% |
|
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. |
60.00% |
|
Clinical management of adrenocortical carcinoma |
60.00% |
|
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses? |
60.00% |
|
Biophysiological effects of Ukrain therapy in a patient with breast cancer (case report) |
60.00% |
|
Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo |
60.00% |
|
Enhanced proliferation and potassium conductance of Schwann cells isolated from NF2 schwannomas can be reduced by quinidine. |
60.00% |
|
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy. |
60.00% |
|
Cancer mortality in six lowest versus six highest elevation jurisdictions in the u.s. |
60.00% |
|
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal...... |
60.00% |
|
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". |
60.00% |
|
Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary |
60.00% |
|
Ukrain therapy of stage T1N0M0 bladder cancer patients |
60.00% |
|
Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glyc |
60.00% |
|
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. |
60.00% |
|
Anti-Cancer Infusions |
60.00% |
|
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. |
60.00% |
|
The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness |
60.00% |
|
Programmed drug delivery: nanosystems for tumor targeting. |
60.00% |
|
Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer...... |
60.00% |
|
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp |
60.00% |
|
N-Acetylcysteine: Multiple Clinical Applications |
60.00% |
|
Ukrain both as an anti cancer and immunoregulatory agent |
60.00% |
|
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer with metronomic UFT + CP |
60.00% |
|
Review on molecular and therapeutic potential of thymoquinone in cancer. |
60.00% |
|
Oncolytic virus therapy for malignant brain tumors |
60.00% |
|
Cysteine proteinases and their inhibitors in the development of mouse HA-1 hepatoma and antineoplastic therapy |
60.00% |
|
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. |
60.00% |
|
Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. |
60.00% |
|
Ukrain |
62.22% |
|
Evaluation of Ukrain as an immunostimulant in patients with various carcinomas. |
63.33% |
|
Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Can |
63.33% |
|
Chelidonium majus L. (Ukrain) in the treatment of cancer patients. |
63.33% |
|
Animal studies on Ukrain |
65.00% |
|
Albarin, Injectable Aloe Vera or Polymannons |
65.00% |
|
Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. |
65.00% |
|
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. |
70.00% |
|
Gastric cancer originating from bone marrow-derived cells. |
70.00% |
|
Oncolytic Virus Treatment |
70.00% |
|
Photodynamic Therapy |
70.00% |
|
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma |
70.00% |
|
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit |
70.00% |
|
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination.............. |
70.00% |
|
Pectin: A Bioactive Food Polysaccharide with Cancer Preventive Potential |
70.00% |
|
Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. |
70.00% |
|
Anticancer Effect of Dihydroartemisinin (DHA) in a Pancreatic Tumor Model Evaluated by Conventional Methods and Optical Imaging. |
70.00% |
|
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. |
70.00% |
|
Ukrain treatment in carcinoma of the oesophagus (case report) |
70.00% |
|
Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemi |
70.00% |
|
Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. |
70.00% |
|
Experimental Radiology |
70.00% |
|
Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. |
70.00% |
|
SONIA POULTON INTERVIEWS DR. MIKAEL NORDFORS CORRUPTED MEDICINE AND ALTERNATIVE TREATMENTS. |
70.00% |
|
Cancer preventive effect of Morinda citrifolia (Noni). |
70.00% |
|
Effects of opioids on the immune system. |
70.00% |
|
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide r |
70.00% |
|
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. |
70.00% |
|
Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119 |
70.00% |
|
In vitro induction of apoptotic cell death in chronic lymphocytic leukemia by two natural products: preliminary study |
70.00% |
|
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-indep.. |
70.00% |
|
Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. |
70.00% |
|
Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo |
70.00% |
|
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer |
70.00% |
|
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. |
70.00% |
|
Brain tumour cells killed by anti-nausea drug |
70.00% |
|
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer |
70.00% |
|
Effect of culture supernatant of Toxoplasma gondii on the proliferation and apoptosis of BGC-823 cells |
70.00% |
|
Proton Therapy |
70.00% |
|
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline |
70.00% |
|
Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. |
70.00% |
|
Cancer Growth and Its Inhibition in Terms of Coherence |
70.00% |
|
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. |
70.00% |
|
Oncologic benefit of tonsillectomy in stage I and II tonsil cancer: a surveillance epidemiology and end results database review |
70.00% |
|
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines |
70.00% |
|
Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. |
70.00% |
|
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). |
70.00% |
|
Cyberknife |
70.00% |
|
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and re |
70.00% |
|
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses |
70.00% |
|
Oireachtas Special Committee on COVID-19 Response |
70.00% |
|
PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation. |
70.00% |
|
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory....... |
70.00% |
|
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. |
70.00% |
|
Efficacy of ukrain in the treatment of pancreatic cancer. |
70.00% |
|
BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
70.00% |
|
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. |
70.00% |
|
Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. |
70.00% |
|
Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. |
70.00% |
|
Digitoxin and its analogs as novel cancer therapeutics. |
70.00% |
|
New techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions. Improved effectiveness and safety? Impact on survival? |
70.00% |
|
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu |
70.00% |
